MDL 100,907: A selective 5-HT(2A) receptor antagonist for the treatment of schizophrenia

CNS Drug Reviews

Volumn 3, Issue 1, 1997, Pages 49-67

  Schmidt, Christopher J ^a,c   Kehne, John H ^a,b   Carr, Albert A ^a  

^a SANOFI   (France)

^b NEUROGEN CORPORATION   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; SEROTONIN 2A ANTAGONIST;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; NEUROTRANSMISSION; NONHUMAN; REVIEW; SCHIZOPHRENIA;

EID: 0030927176     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1997.tb00316.x     Document Type: Review

References (100)

1. Angrist BM, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 1980;72:7-19.
2. Arnt J. Inhibitory effects on the discriminative stimulus properties of D-amphctamine by classic and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system? Psychopharmacology 1996;124:117-125.
3. Baldessarini RJ, Frankenburg FR. Clozapine, a novel antipsychotic agent. N Eng J Med 199I;324:746-754.
4. Braff DL, Stone C, Callaway E, Geyer MA, Click ID, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978;14:339-343.
5. Braff DL, Swerdlow NR, Geyer MA. Gating and habituation deficits in the schizophrenia disorders. Clin Neurosci 1995;3:131-139.
6. Carlsson ML, Carlsson A. The NMDA antagonist, MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Trans 1989;75:221-226.
7. Carlsson M, Carlsson A. Interactions between glutaminergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends in Neurosci 1990;13:272-276.
8. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J Neural Trans 1995;100:225-237.
9. Carpenter WT, Duchanan RW. Schizophrenia. N Eng J Med 1994;330:681-690.
10. Chiodo LA, Dunney BS. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-1619.
11. Corbett R, Hartman H, Kerman LL, et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 1993;45:9-17.
12. Criswell HE, Johnson KB, Mueller RA, Breese GR. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J Pharmacol Exp Ther 1993;265:1001-1010.
13. Crow TJ, Baker HF, Cross AJ, et al. Monoamine mechanisms in chronic schizophrenia: Post-mortem neurochemical findings. Br J Psychiatry 1979;134:249-256.
14. Daniel DG, Weinberger DR, Jones DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 1991;11:1907-1917.
15. 2 receptor antagonist, ritanserin. J Neurochem 1992;594:1459-1466.
16. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopaminergic function measured with positron emission tomography and in vivo microdialysis. J Neurosci 1995;15:821-829.
17. Doran AR, Boronow J, Weinberger DR, Wolkowitz OM, Breier A, Pickar D. Structural brain pathology in schizophrenia revisited: prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology 1987;1:25-31.
18. 2 receptors. Drug Dev Res 1988;13:29-43.
19. 1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacohgy 1989;2:191-199.
20. Fadayel GM, Ring SC, Dinerstein RJ, Schmidt CJ. Characterization of the increase in medial prefrontal cortex dopamine release produced in the rat by the putative antipsychotic, MDL 100,907. Abstr Soc Neurosci 1995;
21. Farley IJ, Shannak KS, Hornykiewicz O. Brain monoamine changes in chronic paranoid schizophrenia and their possible relationship to increased receptor sensitivity. In: Pepeu G, Kuhar MJ, Enna SJ, eds. Receptors for Neurotransmitters and Peptides. New York: Raven Press 1980:427-433.
22. Freedman B, Chapman L. Early subjective experiences in schizophrenic episodes. J Abnormal Psychol 1973;82:46-54.
23. Freeman AS, Bunney BS. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 1984;104:287-293.
24. French ED. Effects of phencyclidine on ventral tegmental AlO dopamine neurons in the rat. Neuropharmacology 1986;25:241-248.
25. French ED, Mura A, Wang T. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 1993;13:108-116.
26. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine, and serotonin subtype selective antagonists in mice (submitted).
27. 2 antagonist, in electrophysiological effects predictive of antipsychotic activity. J Pharmacol Exp Ther 1989;249:673-680.
28. Goldstein JM, Litwin LC, Sutton EB, Malick JB. SEROQUEL: electrophysiological profile of a potential atypical antipsychotic agent. Psychopharmacology 1993;112:293-298.
29. Goldberg TE, Weinberger DR, Herman KF, Pliskin NH, Podd MH. Further evidence for dementia of the prefrontal type in schizophrenia. Arch Gen Psychiatry 1987;44:1008-1014.
30. Gouzoulis E, Hermle L, Sass H. Psychedelic experiences at the onset of productive episodes of endogenous psychosis. Nervenarzt 1994;65:198-201.
31. 2A occupancy in the human brain alter a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 1996 (in press).
32. Gur RE. Functional brain-imaging studies in schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press 1995:1185-1192.
33. 2A receptors with PET. Abstr Soc Nuclear Med 1996.
34. 2A antagonist, with clozapine and haloperidol. Brain Res Bull 1996 (in press).
35. Hansson LO, Waters N, Winblad B, Gottfries C-G, Carlsson A. Evidence for biochemical heterogeneity in schizophrenia: A multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Trans 1994;98:217-235.
36. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
37. 2A receptor ligand. Naunyn Schmiedeberg's Arch Pharmacol 1996;354:205-209.
38. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993;8:315-336.
39. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996;277:968-981.
40. 2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 1996;15:116-124.
41. Kleinman JE, Laruelle M, Joyce JN, Casanova MF. Abnormalities of serotonergic neural transmission in prefrontal cortex in schizophrenia, Clin Neuropharmacol (Suppl 1) 1992;15:397-398.
42. Knable MB, Weinberger DR. Limbic-prefrontal connectivity and clozapine. J Clin Psychiatry (Suppl B) 1994;55:70-73.
43. Korpi ER, Kleinman JE, Goodman SI, et al. Serotonin and 5-Hydroxyindoleacetic acid in the brains of suicide victims: Comparison in chronic schizophrenic patients with suicide as cause of death. Arch Gen Psychiatry 1986;43:594-600.
44. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic doses of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
45. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19.
46. Langs RJ, Barr HL. Lysergic acid diethylamine and schizophrenic reactions. J Mental Nervous Disease 1968;147:163-172.
47. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiat Scand (Suppl 380) 1994;89:8-13.
48. 2 receptors. Psychopharmacology 1993;112: S40-S54.
49. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry (Suppl) 1993;22:7-18.
50. Loscher W, Honack D. The behavioral effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 1992;215:199-208.
51. 2A receptors with positron emission tomography (submitted).
52. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-307.
53. Mansbach RS, Geyer MA. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 1989;2:299-308.
54. Mansbach RS, Geyer MA, Braff DL. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 1988;94:507-514.
55. 2A receptors. Eur J Pharmacol 1995;280:R9-11.
56. Moghaddam BJ. Preferential activation of cortical dopamine neurotransmission by clozapine: Functional significance. Clin Psychiatry 1994;55:27-29.
57. 2A antagonist. Behav Brain Res 1996;73:163-167.
58. Murase S, Mathe JM, Grenhoff J, Svensson TH. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: Differential action on firing pattern related to anatomical localization. J Neural Trans 1993;91:13-25.
59. Nash JF. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 1990;47:2401-2408.
60. Nash JF, Meltzer HY, Gudelsky GA. Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. J Neurochem 1990;54:1062-1067.
61. 2A antagonist. Abstr Am Coll Neuropsychopharmacol 1996 (in press).
62. 2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology 1993;111:427-434.
63. Ouagazzal A, Nieoullon A, Amalric M. Locomotor activation induced by MK-801 in the rat: Postsynaptic interactions with dopamine receptors in the ventral striatum. Eur J Pharmacol 1994;251:229-236.
64. 2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopliarinacology 1996;124:107-116.
65. 3 mediated control of dopaminergic function. Psychopliarinacology (Suppl) 1993;112:60-67.
66. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interactions in the rat ventral tegmental area: An electrophysiological study in vivo. J Pharmacol Exp Ther 1994;271:83-90.
67. Prisco S, Esposito E. Differential effects of acute and chronic iluoxetine administration on the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Dr J Pharmacol 1995;116:1923-1931.
68. Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 1992;46:315-328.
69. Robertson GS, Matsumura, Fibiger HC. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058-1066.
70. Robertson GS, Fibiger HC. Effects of olanzapine on regional c-fos expression in the forebrain. Neuropsychopharmacology 1996;14:105-110.
71. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytrypatamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-1410.
72. Roth UL, Meltzer UY. The role of serotonin in schizophrenia. In: Bloom F, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press 1995:1215-228.
73. Sams-Dodd F. Phencyclidine induced stereotyped behaviour and social isolation in rats: A possible animal model of schizophrenia. Behav Pharmacol 1996;7:3-23.
74. Schlemmer RF, Young JE, Davis JM. Stimulant induced disruption of non-human primate social behavior and the psychopharmacology of schizophrenia. J Psychopharmacol 1996 (in press).
75. Schmidt CJ, Abbate GM, Black CK, Taylor VL. Selective 5-hydroxytryptamine-2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1990;255:478-483.
76. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L-DOPA. J Pharmacol Exp Ther 1991;256:230-235.
77. 2 receptor antagonist, MDL28.133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of MDMA. Eur J Pharmacol 1992;220:151-159.
78. 2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992;223:65-74.
79. 2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol (Suppl 2) 1993;8:25-32.
80. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 1994;62:1382-389.
81. 2A antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995;273:273-279.
82. 2A receptors in schizophrenia. Life Sci 1995;56:2209-2222.
83. 2A receptor blockade. J Pharmacol Exp Ther 1996;227:1541-1549.
84. Schreiber R, Brocco M, Millan MJ. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the atypical antipsychotics clozapine and risperidone. Eur J Pharmacol 1994;264:99-102.
85. 1A agonists. J Pharmacol Exp Ther 1995;273:101-112.
86. 2C receptors. Behav Pharmacol 1995;6:839-842.
87. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: Acute and repeated treatment. Synapse 1992;10:25-33.
88. Snyder SH. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am J Psychiatry 1976;133:197-202.
89. 2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. J Pharmacol Exp Ther 1992;260:872-878.
90. 2 receptor antagonist, MDL 100,907, as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies J Pharmacol Exp Ther 1993;266:684-691.
91. 2A antagonist MDL 100,907 blocks dizocilpine-induced increases in the firing rate of A10 dopaminergic neurons. Schizophrenia Res 1995;15:21.
92. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104.
93. 2 antagonist, activates midbrain dopaminergic neurons by blocking serotonergic inhibition. Psychopharmacology 1989,98:45-50.
94. van Giersbergen P, Sorensen SM. In vitro and ex vivo binding profile of MDL 100,907, a new putative antipsychotic drug. In: Macher JP, Crocq MA, eds. The Bio-Clinical Interface. Paris: John Libbey Eurotext 1996.
95. Wan W, Ennulat DJ, Cohen BM. Acute administration of typical and atypical antipsychotic agents induced distinctive patterns of fos expression in the rat forebrain. Brain Res 1995;588:95-104.
96. Waters N, Carlsson A, Hansson L. An animal model of schizophrenia based on multivariate analysis of monoaminergic biochemistry and behavior. Abstr Soc Neurosci 1994;20:825.
97. Weinberger DR, German KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence of a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609-615.
98. 2A receptors with C-11 MDL 100,907. Abstr Soc Nuclear Med 1996.
99. Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci 1954;40:228-231.
100. Zhang J, Chiodo LA, Freeman AS. Influence of excitatory amino acid receptor subtypes on the electrophysiological activity of dopaminergic and nondopaminergic neurons in rat substantia nigra. J Pharmacol Exp Ther 1994;269:313-321.